Amar U Kishan1, Fang-I Chu2, Christopher R King2, Wendy Seiferheld3, Daniel E Spratt4, Phuoc Tran5, Xiaoyan Wang6, Stephanie E Pugh3, Kiri A Sandler2, Michel Bolla7, Philippe Maingon8, Theo De Reijke9, Nicholas G Nickols10, Matthew Rettig11, Alexandra Drakaki12, Sandy T Liu12, Robert E Reiter13, Albert J Chang2, Felix Y Feng14, Dipti Sajed15, Paul L Nguyen16, Patrick A Kupelian2, Michael L Steinberg2, Paul C Boutros17, David Elashoff6, Laurence Collette18, Howard M Sandler19. 1. Department of Radiation Oncology, University of California, Los Angeles, CA, USA; Department of Urology, University of California, Los Angeles, CA, USA. Electronic address: aukishan@mednet.ucla.edu. 2. Department of Radiation Oncology, University of California, Los Angeles, CA, USA. 3. NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA. 4. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA. 5. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6. Department of General Internal Medicine and Health Services Research, University of California, Los Angeles, CA, USA. 7. Department of Radiation Oncology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France. 8. Centre Georges-François Leclerc, Dijon, France; Sorbonne Université Paris, Paris, France. 9. Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. 10. Department of Radiation Oncology, University of California, Los Angeles, CA, USA; Department of Radiation Oncology, Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 11. Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Division of Hematology and Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 12. Division of Hematology and Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 13. Department of Urology, University of California, Los Angeles, CA, USA. 14. Departments of Radiation Oncology, Urology, and Medicine, University of California, San Francisco, CA, USA. 15. Department of Pathology, University of California, Los Angeles, CA, USA. 16. Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 17. Department of Urology, University of California, Los Angeles, CA, USA; Department of Human Genetics, University of California, Los Angeles, CA, USA. 18. European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium. 19. Department of Radiation Oncology, Cedars Sinai, Los Angeles, CA, USA.
Abstract
BACKGROUND: The importance of local failure (LF) after treatment of high-grade prostate cancer (PCa) with definitive radiotherapy (RT) remains unknown. OBJECTIVE: To evaluate the clinical implications of LF after definitive RT. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data meta-analysis of 992 patients (593 Gleason grade group [GG] 4 and 399 GG 5) enrolled in six randomized clinical trials. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox proportional hazard models were developed to evaluate the relationship between overall survival (OS), PCa-specific survival (PCSS), and distant metastasis (DM)-free survival (DMFS) and LF as a time-dependent covariate. Markov proportional hazard models were developed to evaluate the impact of specific transitions between disease states on these endpoints. RESULTS AND LIMITATIONS: Median follow-up was 6.4 yr overall and 7.2 yr for surviving patients. LF was significantly associated with OS (hazard ratio [HR] 1.70 [95% confidence interval {CI} 1.37-2.10]), PCSS (3.10 [95% CI 2.33-4.12]), and DMFS (HR 1.92 [95% CI 1.54-2.39]), p < 0.001 for all). Patients who had not transitioned to the LF state had a significantly lower hazard of transitioning to a PCa-specific death state than those who transitioned to the LF state (HR 0.13 [95% CI 0.04-0.41], p < 0.001). Additionally, patients who transitioned to the LF state had a greater hazard of DM or death (HR 2.46 [95% CI 1.22-4.93], p = 0.01) than those who did not. CONCLUSIONS: LF is an independent prognosticator of OS, PCSS, and DMFS in high-grade localized PCa and a subset of DM events that are anteceded by LF events. LF events warrant consideration for intervention, potentially suggesting a rationale for upfront treatment intensification. However, whether these findings apply to all men or just those without significant comorbidity remains to be determined. PATIENT SUMMARY: Men who experience a local recurrence of high-grade prostate cancer after receiving upfront radiation therapy are at significantly increased risks of developing metastases and dying of prostate cancer.
BACKGROUND: The importance of local failure (LF) after treatment of high-grade prostate cancer (PCa) with definitive radiotherapy (RT) remains unknown. OBJECTIVE: To evaluate the clinical implications of LF after definitive RT. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data meta-analysis of 992 patients (593 Gleason grade group [GG] 4 and 399 GG 5) enrolled in six randomized clinical trials. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox proportional hazard models were developed to evaluate the relationship between overall survival (OS), PCa-specific survival (PCSS), and distant metastasis (DM)-free survival (DMFS) and LF as a time-dependent covariate. Markov proportional hazard models were developed to evaluate the impact of specific transitions between disease states on these endpoints. RESULTS AND LIMITATIONS: Median follow-up was 6.4 yr overall and 7.2 yr for surviving patients. LF was significantly associated with OS (hazard ratio [HR] 1.70 [95% confidence interval {CI} 1.37-2.10]), PCSS (3.10 [95% CI 2.33-4.12]), and DMFS (HR 1.92 [95% CI 1.54-2.39]), p < 0.001 for all). Patients who had not transitioned to the LF state had a significantly lower hazard of transitioning to a PCa-specific death state than those who transitioned to the LF state (HR 0.13 [95% CI 0.04-0.41], p < 0.001). Additionally, patients who transitioned to the LF state had a greater hazard of DM or death (HR 2.46 [95% CI 1.22-4.93], p = 0.01) than those who did not. CONCLUSIONS: LF is an independent prognosticator of OS, PCSS, and DMFS in high-grade localized PCa and a subset of DM events that are anteceded by LF events. LF events warrant consideration for intervention, potentially suggesting a rationale for upfront treatment intensification. However, whether these findings apply to all men or just those without significant comorbidity remains to be determined. PATIENT SUMMARY:Men who experience a local recurrence of high-grade prostate cancer after receiving upfront radiation therapy are at significantly increased risks of developing metastases and dying of prostate cancer.
Authors: Deborah A Kuban; Susan L Tucker; Lei Dong; George Starkschall; Eugene H Huang; M Rex Cheung; Andrew K Lee; Alan Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2007-08-31 Impact factor: 7.038
Authors: Jeff M Michalski; Jennifer Moughan; James Purdy; Walter Bosch; Deborah W Bruner; Jean-Paul Bahary; Harold Lau; Marie Duclos; Matthew Parliament; Gerard Morton; Daniel Hamstra; Michael Seider; Michael I Lock; Malti Patel; Hiram Gay; Eric Vigneault; Kathryn Winter; Howard Sandler Journal: JAMA Oncol Date: 2018-06-14 Impact factor: 31.777
Authors: Sophie D Fosså; Fredrik Wiklund; Olbjørn Klepp; Anders Angelsen; Arne Solberg; Jan-Erik Damber; Morten Hoyer; Anders Widmark Journal: Eur Urol Date: 2016-03-26 Impact factor: 20.096
Authors: Malcolm D Mason; Wendy R Parulekar; Matthew R Sydes; Michael Brundage; Peter Kirkbride; Mary Gospodarowicz; Richard Cowan; Edmund C Kostashuk; John Anderson; Gregory Swanson; Mahesh K B Parmar; Charles Hayter; Gordana Jovic; Andrea Hiltz; John Hetherington; Jinka Sathya; James B P Barber; Michael McKenzie; Salah El-Sharkawi; Luis Souhami; P D John Hardman; Bingshu E Chen; Padraig Warde Journal: J Clin Oncol Date: 2015-02-17 Impact factor: 44.544
Authors: Michael Xiang; Ting Martin Ma; Ricky Savjani; Erqi L Pollom; R Jeffrey Karnes; Tristan Grogan; Jessica K Wong; Giovanni Motterle; Jeffrey J Tosoian; Bruce J Trock; Eric A Klein; Bradley J Stish; Robert T Dess; Daniel E Spratt; Avinash Pilar; Chandana Reddy; Rebecca Levin-Epstein; Trude B Wedde; Wolfgang A Lilleby; Ryan Fiano; Gregory S Merrick; Richard G Stock; D Jeffrey Demanes; Brian J Moran; Hartwig Huland; Phuoc T Tran; Santiago Martin; Rafael Martinez-Monge; Daniel J Krauss; Eyad I Abu-Isa; Ridwan Alam; Zeyad Schwen; Thomas M Pisansky; C Richard Choo; Daniel Y Song; Stephen Greco; Curtiland Deville; Todd McNutt; Theodore L DeWeese; Ashley E Ross; Jay P Ciezki; Paul C Boutros; Nicholas G Nickols; Prashant Bhat; David Shabsovich; Jesus E Juarez; Natalie Chong; Patrick A Kupelian; Matthew B Rettig; Nicholas G Zaorsky; Alejandro Berlin; Jonathan D Tward; Brian J Davis; Robert E Reiter; Michael L Steinberg; David Elashoff; Eric M Horwitz; Rahul D Tendulkar; Derya Tilki; Johannes Czernin; Andrei Gafita; Tahmineh Romero; Jeremie Calais; Amar U Kishan Journal: JAMA Netw Open Date: 2021-12-01
Authors: Tommy Jiang; Daniela Markovic; Jay Patel; Jesus E Juarez; Ting Martin Ma; David Shabsovich; Nicholas G Nickols; Robert E Reiter; David Elashoff; Matthew B Rettig; Nicholas G Zaorsky; Daniel E Spratt; Amar U Kishan Journal: Prostate Cancer Prostatic Dis Date: 2021-08-16 Impact factor: 5.554
Authors: Amar U Kishan; R Jeffrey Karnes; Tahmineh Romero; Jessica K Wong; Giovanni Motterle; Jeffrey J Tosoian; Bruce J Trock; Eric A Klein; Bradley J Stish; Robert T Dess; Daniel E Spratt; Avinash Pilar; Chandana Reddy; Rebecca Levin-Epstein; Trude B Wedde; Wolfgang A Lilleby; Ryan Fiano; Gregory S Merrick; Richard G Stock; D Jeffrey Demanes; Brian J Moran; Michelle Braccioforte; Hartwig Huland; Phuoc T Tran; Santiago Martin; Rafael Martínez-Monge; Daniel J Krauss; Eyad I Abu-Isa; Ridwan Alam; Zeyad Schwen; Albert J Chang; Thomas M Pisansky; Richard Choo; Daniel Y Song; Stephen Greco; Curtiland Deville; Todd McNutt; Theodore L DeWeese; Ashley E Ross; Jay P Ciezki; Paul C Boutros; Nicholas G Nickols; Prashant Bhat; David Shabsovich; Jesus E Juarez; Natalie Chong; Patrick A Kupelian; Anthony V D'Amico; Matthew B Rettig; Alejandro Berlin; Jonathan D Tward; Brian J Davis; Robert E Reiter; Michael L Steinberg; David Elashoff; Eric M Horwitz; Rahul D Tendulkar; Derya Tilki Journal: JAMA Netw Open Date: 2021-07-01
Authors: Natalie Kurganovs; Hanzhi Wang; Xiaoyong Huang; Vladimir Ignatchenko; Andrew Macklin; Shahbaz Khan; Michelle R Downes; Paul C Boutros; Stanley K Liu; Thomas Kislinger Journal: Proteomics Clin Appl Date: 2021-06-30 Impact factor: 3.603